Minerva’s Schizophrenia Drug Application Accepted by FDA
Minerva Neurosciences, Inc . NERV announced that the FDA has accepted its Investigational New Drug (IND) application for pipeline candidate MIN-101. Minerva is developing MIN-101, a first-in-class 5-HT2a and sigma2 antagonist, for the treatment of schizophrenia […]